EU aims to buy 180-million doses of Pfizer’s Omicron-tailored vaccine
17 December 2021 - 13:46
byFrancesco Guarascio
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Brussels — EU governments have agreed to exercise an option to buy more than 180-million doses of a version of the Covid-19 vaccine adapted for the Omicron variant developed by BioNTech and Pfizer, the head of the European Commission said.
Pfizer and BioNTech began development of a prototype Omicron-specific Covid-19 vaccine on November 25, and said they could have it ready in March.
“The member states have agreed to trigger a first tranche of over 180-million extra doses of adapted vaccines, in our third contract with BioNTech-Pfizer,” Ursula von der Leyen told a news conference on Thursday night at the end of a regular summit with EU leaders.
The EU’s latest contract with Pfizer and BioNTech allows EU states to buy up to 1.8-billion doses through 2023, of which half have already been ordered and the other half are optional.
Pfizer said no optional doses had been ordered yet and talks with the EU for their possible supply had so far not concerned adapted versions of the vaccine.
“At this time, discussions with the EC [European Commission] about the potential for additional supply pursuant to their option rights under our agreement are not specific to an adapted vaccine,” Pfizer said in a statement on Friday.
“While we believe we can deliver an adapted vaccine in March 2022, we do not yet know whether this will be needed and availability will require authorisation by regulatory authorities,” Pfizer said.
Spokespeople for the European Commission were not immediately available to give more details about the announcement.
The European Medicines Agency has so far said that there is no conclusive evidence an adapted vaccine is needed against Omicron.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
EU aims to buy 180-million doses of Pfizer’s Omicron-tailored vaccine
Brussels — EU governments have agreed to exercise an option to buy more than 180-million doses of a version of the Covid-19 vaccine adapted for the Omicron variant developed by BioNTech and Pfizer, the head of the European Commission said.
Pfizer and BioNTech began development of a prototype Omicron-specific Covid-19 vaccine on November 25, and said they could have it ready in March.
“The member states have agreed to trigger a first tranche of over 180-million extra doses of adapted vaccines, in our third contract with BioNTech-Pfizer,” Ursula von der Leyen told a news conference on Thursday night at the end of a regular summit with EU leaders.
The EU’s latest contract with Pfizer and BioNTech allows EU states to buy up to 1.8-billion doses through 2023, of which half have already been ordered and the other half are optional.
Pfizer said no optional doses had been ordered yet and talks with the EU for their possible supply had so far not concerned adapted versions of the vaccine.
“At this time, discussions with the EC [European Commission] about the potential for additional supply pursuant to their option rights under our agreement are not specific to an adapted vaccine,” Pfizer said in a statement on Friday.
“While we believe we can deliver an adapted vaccine in March 2022, we do not yet know whether this will be needed and availability will require authorisation by regulatory authorities,” Pfizer said.
Spokespeople for the European Commission were not immediately available to give more details about the announcement.
The European Medicines Agency has so far said that there is no conclusive evidence an adapted vaccine is needed against Omicron.
Reuters
Covid-19 hospital cases up 70% in past week‚ but actual numbers very low
US CDC recommends Moderna and Pfizer over J&J
More than 90% of recent Covid-19 deaths either unvaxxed or partly vaccinated
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.